Summary
In nine patients, the synthesis rate Rsyn of the vitamin K-dependent clotting factors was calculated from changes in prothrombin-complex activity after intravenous administration of a synthesis-blocking dose of phenprocoumon (PPC). The biological half-life of PPC was between 2.70 and 7.01 days. No correlation was found between the level of the free fraction of this strongly protein-bound drug and its biological half-life. There was a positive correlation (p<0.01) between the size of the free fraction of PPC and the apparent volume of distribution of the drug. Four of the patients had had an acute myocardial infarction and they showed increased sensitivity to PPC. In them the plasma level of PPC sufficient to reduce Rsyn to 50% of R°syn was significantly lower, and the depression of individual vitamin K-dependent coagulation factors was more pronounced and prolonged, than in five other patients with chronic disease. The degradation rate of coagulation factors was also found to be higher in the patients with acute myocardial infarction. In four patients with chronic disease, anticoagulant therapy with PPC was continued in the out-patient clinic. The calculated oral maintenance dose of PPC, assuming complete absorption, first-order elimination kinetics and a linear relationship between the pharmacological effect and the logarithm of the PPC-plasma concentration, showed good agreement with the dose actually found to produce the desired PP% level.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aggeler, P.M., O'Reilly, R.A.: Pharmacological basis of oral anticoagulant therapy. Thrombos. Diathes. haemorrh. (Stuttg.) Suppl.21, 227–256 (1966)
Bieger, R., de Jonge, H., Loeliger, E.A.: Influence of nitrazepam on oral anticoagulation with phenprocoumon. Clin. Pharmacol. Ther.13, 361–365 (1972)
Breckenridge, A., Orme, M.L.E., Thorgeirsson, S., Davies, D.S., Brooks, R.V.: Drug interactions with warfarin: Studies with dichloralphenazone, chloral hydrate and phenazone (antipyrine). Clin. Sci.40, 351–364 (1971)
Chriske, H.W., Gross, R., Hilger, H.H., Oette, K., Smekal, P. v., Knabe, M., Kray, D.: Pharmakokinetische Untersuchungen zur Phenprocoumon (Marcoumar)-Resistenz. Verh. dtsch. Ges. inn. Med.79, 1311–1314 (1973a)
Chriske, H.W., Smekal, P. v., Knabe, M., Kray, D.: Pharmakokinetische Untersuchungen bei erhöhter Ansprechbarkeit gegenüber Phenprocoumon (Marcumar®). Med. Welt. (Berl.)24, 1620–1621 (1973 b)
Foged, L., Husted, S., Andreasen, F.: Protein binding of phenprocoumon in the absence and presence of furosemide. Acta pharmacol. (Kbh.)39, 312–320 (1976)
Glogner, P., Heni, N.: Pharmakokinetik und Metabolismus von Phenprocoumon — “Marcumar” beim Menschen. Verh. dtsch. Ges. inn. Med.79, 1308–1310 (1973)
Hayes, M.J., Langman, M.J.S., Short, A.H.: Changes in drug metabolism with increasing age: 1 Warfarin binding and plasma proteins. Brit. J. clin. Pharmacol.2, 69–72 (1975)
Husted, S., Andreasen, F.: Problems encountered in long-term treatment with anticoagulants. Acta med. scand.200, 379–384 (1976a)
Husted, S., Andreasen, F., Foged, L.: Increased sensitivity to phenprocoumon during methyltestoterone therapy. Europ. J. clin. Pharmacol.10, 209–216 (1976b)
Husted, S., Andreasen, F., Foged, L.: Unpublished data, 1976 c
Jähnchen, E., Levy, G.: Relationship between distribution, elimination and anticoagulant action of dicumarol. J. Pharmacol. exp. Ther.188, 293–299 (1974)
Koch-Weser, J., Sellers, M.: Drug interaction with coumarin anticoagulants (first of two parts). New. Engl. J. Med.285, 487–498 (1971)
Levy, G.: Comparative pharmacokinetics of the anticoagulant effect of coumarin drugs in man and rat. J. Pharmacokinet. Biopharm.1, 541–551 (1973)
Martin, B.K.: Potential effect of the plasma proteins on drug distribution. Nature207, 274–276 (1965)
Nagashima, R., O'Reilly, R.A., Levy, G.: Kinetics of pharmacologic effects in man: The anticoagulant action of warfarin. Clin. Pharmacol. Ther.10, 22–35 (1969)
O'Reilly, R.A., Aggeler, P.M.: Determinants of the response to oral anticoagulant drugs in man. Pharmacol. Rev.22, 35–96 (1970)
O'Reilly, R.A., Levy, G.: Pharmacokinetic analysis of potentiating effect of phenylbutazone on anticoagulant action of warfarin in man. J. pharm. Sci.59, 1258–1261 (1970)
Peyman, M.A.: The significance of haemorrhage during the treatment of patients with the coumarin anticoagulants. Acta med. scand. Suppl.339, 1–62 (1958)
Ristola, P., Pyörälä, K.: Determinants of the response to coumarin anticoagulants in patients with acute myocardial infarction. Acta med. scand.192, 183–188 (1972)
Sellers, E.M., Koch-Weser, J.: Potentiation of warfarin-induced hypoprothombinemia by chloral hydrate. New. Engl. J. Med.283, 827–831 (1970)
Stenbjerg, S., Husted, S., Mygind, K.: A circulating factor V inhibitor: Possible side effect of treatment with streptomycin. Scand. J. Haemat.14, 280–285 (1975)
Vesell, E.S., Page, J.G.: Genetic control of dicumarol levels in man. J. clin. Invest.47, 2657–2663 (1968)
Weder, H.G., Schildknecht, J., Kesselring, P.: A new equilibrium dialyzing system. Amer. Lab.10, 15–21 (1971)
Yacobi, A., Levy, G.: Comparative pharmacokinetics of coumarin anticoagulants XIV: Relationship between protein binding, distribution, and elimination kinetics of warfarin in rats. J. pharm. Sci.64, 1660–1664 (1975)
Yacobi, A., Wingard, L.B., Levy, G.: Comparative pharmacokinetics of coumarin anticoagulants X: Relationship between distribution, elimination, and anticoagulant action of warfarin. J. pharm. Sci.63, 168–872 (1974)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Husted, S., Andreasen, F. Individual variation in the response to phenprocoumon. Eur J Clin Pharmacol 11, 351–358 (1977). https://doi.org/10.1007/BF00566532
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00566532